Development of a biocompatible nanodelivery system for tuberculosis drugs based on isoniazid-Mg/Al layered double hydroxide

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 4749-4762

  Saifullah, Bullo ^a   Palanisamy, Arulselvan ^b   Ezzat El Zowalaty, Mohamed ^c   Fakurazi, Sharida ^b,d   Webster, Thomas J ^e,f   Geilich, Benjamin M ^e   Hussein, Mohd Zobir ^a  

^a Institute of Advanced Technology   (Malaysia)

^b Institute of Bioscience   (Malaysia)

^c JAZAN UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^e Northeastern University   (United States)

^f KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Isoniazid; Mg Al LDH; Nanodelivery system; Tuberculosis

Indexed keywords

HYDROXIDE; ISONIAZID; MAGNESIUM ALUMINUM LAYERED DOUBLE HYDROXIDE; UNCLASSIFIED DRUG; ALUMINUM HYDROXIDE; ALUMINUM HYDROXIDE, MAGNESIUM HYDROXIDE, DRUG COMBINATION; DRUG COMBINATION; MAGNESIUM HYDROXIDE; NANOCOMPOSITE; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NANODELIVERY SYSTEM; NANOMEDICINE; NONHUMAN; TUBERCULOSIS; 3T3 CELL LINE; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; PROCEDURES;

ALUMINUM HYDROXIDE; ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE; CELL SURVIVAL; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; HUMANS; ISONIAZID; MAGNESIUM HYDROXIDE; MICE; MYCOBACTERIUM TUBERCULOSIS; NANOCOMPOSITES; NIH 3T3 CELLS;

EID: 84907880256     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S63608     Document Type: Article

References (43)

1. Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120(4):316–353.
2. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev RespirDis. 1993;147(5): 1311–1320.
3. World Health Organization. Global tuberculosis report 2013. WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. 2013. http://www.who.int/tb/publications/global_report/en/.Accessed August 12, 2014.
4. Saifullah B, Hussein MZ, Hussein Al-Ali SH. Controlled-release approaches towards the chemotherapy of tuberculosis. In J nanomedicine. 2012;7:5451–5463.
5. UNAIDS WHOGTPa. Policy statement on preventive therapy against tuberculosis in people living with HIV. 1998. http://whqlibdoc.who.int/hq/1998/WHO_TB_98.255.pdf. Accessed August 12, 2014.
6. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. JCEH. 2013;3(1):37–49.
7. Vidrio H, Medina M, Fernández G, Lorenzana-Jiménez M, Campos AE. Enhancement of hydralazine hypotension by low doses of isoniazid: Possible role of semicarbazide-sensitive amine oxidase inhibition. Gen Pharmacol-vasc S. 2000;35(4):195–204.
8. Schaberg TKR, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026–2030.
9. Tafazoli S, Mashregi M, O’Brien PJ. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. TAAP. 2008;229(1):94–101.
10. van Hest R, Baars H, Kik S, et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. IDSA. 2004;39(4):488–496.
11. Clemens DL, Lee BY, Xue M, et al. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. AAC. 2012;56(5):2535–2545.
12. Foradada M, Pujol MD, Bermudez J, Estelrich J. Chemical degradation of liposomes by serum components detected by NMR. Chem Phys Lipids. 2000;104(2):133–148.
13. Marques AP, Reis RL, Hunt JA. Cytokine secretion from mononuclear cells cultured in vitro with starch-based polymers and poly-L-lactide. J Biomed Mater Res A. 2004;71(3):419–429.
14. Lam KH, Schakenraad JM, Esselbrugge H, Feijen J, Nieuwenhuis P. The effect of phagocytosis of poly(L-lactic acid) fragments on cellular morphology and viability. J Biomed Mater Res A. 1993; 27(12):1569–1577.
15. Wang Q, O’Hare D. Recent advances in the synthesis and application of layered double hydroxide (LDH) nanosheets. Chem rev J. 2012; 112(7):4124–4155.
16. Rives V. Applied Clay Science. In: Layered double hydroxides: present and future. Nova Science Publishers, Inc., New York, 2001; 22(1/2):75–76.
17. Duan X., David G, editors,. Layered Double Hydroxides; Series: Structure and Bonding. Vol 119. Springer 2006
18. Newman SP, Jones W. Synthesis, characterization and applications of layered double hydroxides containing organic guests. New J Chem. 1998;22(2):105–115.
19. Cavani F, Trifirò F, Vaccari A. Hydrotalcite-type anionic clays: Preparation, properties and applications. Catalysis Today. 1991;11(2): 173–301.
20. Shi L, Li D, Wang J, Li S, Evans DG, Duan X. Synthesis, flame-retardant and smoke-suppressant properties of a borate-intercalated layered double hydroxide. Clay Clay Miner. 2005;53(3):294–300.
21. Yu J, Chung H-E, Choi S-J. Acute oral toxicity and kinetic behaviors of inorganic layered nanoparticles. J Nanomater. 2013;2013:8.
22. Barahuie F, Hussein MZ, Hussein Al-Ali SH, Arulselvan P, Fakurazi S, Zainal Z. Preparation and controlled-release studies of a protocatechuic acid-magnesium/aluminum-layered double hydroxide nanocomposite. Int J Nanomedcine. 2013;8:1975–1987.
23. Kura AU, Hussein Al-Ali SH, Hussein MZ, Fakurazi S, Arulselvan P. Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Int J Nanomedcine. 2013;8:1103–1110.
24. Hussein Al-Ali SH, Al-Qubaisi M, Hussein MZ, Ismail M, Zainal Z, Hakim MN. In vitro inhibition of histamine release behavior of cetirizine intercalated into Zn/Aland Mg/Al-layered double hydroxides. Int J Mol Sci. 2012;13(5):5899–5916.
25. Kong X, Shi S, Han J, Zhu F, Wei M, Duan X. Preparation of glycy-l-tyrosine intercalated layered double hydroxide film and its in vitro release behavior. J Chem Eng. 2010;157(2–3):598–604.
26. Zhang H, Ouyang D, Murthy V, Wong Y, Xu Z, Smith SC. Hydrotalcite intercalated siRNA: computational characterization of the interlayer environment. Pharmaceutics. 2012;4(2):296–313.
27. Mohsin SM, Hussein MZ, Sarijo SH, Fakurazi S, Arulselvan P, Hin TY. Synthesis of (cinnamate-zinc layered hydroxide) intercalation compound for sunscreen application. Chem Cent J. 2013;7(1):26.
28. Wang J, Zhu R, Gao B, et al. The enhanced immune response of hepatitis B virus DNA vaccine using SiO2-LDH nanoparticles as an adjuvant. Biomaterials. 2014;35(1):466–478.
29. Oh JM, Choi SJ, Lee GE, Kim JE, Choy JH. Inorganic metal hydroxide nanoparticles for targeted cellular uptake through clathrin-mediated endocytosis. Chem Asian J. 2009;4(1):67–73.
30. Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Ismail M, Zainal Z, Hakim MN. Comparative study of Mg/Aland Zn/Al-layered double hydroxide-perindopril erbumine nanocomposites for inhibition of angiotensin-converting enzyme. Int J Nanomedicine. 2012;7: 4251–4262.
31. Walters SB, Hanna BA. Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method. JCM. 1996;34(6):1565–1567.
32. Palaci M, Ueki SY, Sato DN, et al. Evaluation of mycobacteria growth indicator tube for recovery and drug susceptibility testing of Mycobacterium tuberculosis isolates from respiratory specimens. JCM. 1996;34(3):762–764.
33. Usman MS, El Zowalaty ME, Shameli K, Zainuddin N, Salama M, Ibrahim NA. Synthesis, characterization, and antimicrobial properties of copper nanoparticles. Int J Nanomedicine. 2013;8:4467.
34. Saifullah B, Hussein MZ, Hussein-Al-Ali SH, Arulselvan P, Fakurazi S. Sustained release formulation of an anti-tuberculosis drug based on para-amino salicylic acid-zinc layered hydroxide nanocomposite. Chem Cent J. 2013;7(1):72.
35. Saifullah B, Hussein MZ, Hussein-Al-Ali SH, Arulselvan P, Fakurazi S. Antituberculosis nanodelivery system with controlled-release properties based on para-amino salicylate-zinc aluminum-layered double-hydroxide nanocomposites. Drug Des Devel Ther. 2013;7:1365–1375.
36. Chih-Chun Wen, Hui-Ming Chen, Swey-Shen Chen, et al. Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines. JBSR. 2011;18:44.
37. Parida KM, Mohapatra L. Carbonate intercalated Zn/Fe layered double hydroxide: A novel photocatalyst for the enhanced photo degradation of azo dyes. Chem Eng J. 2012;179(0):131–139
38. Akyuz S, Akyuz T. FT-IR and FT-Raman spectroscopic studies of adsorption of isoniazid by montmorillonite and saponite. Vibrational Spectroscopy. 2008;48(2):229–232.
39. Gunasekaran S, Sailatha E, Seshadri S, Kumaresan S. FTIR, FT Raman spectra and molecular structural confirmation of isoniazid. IJPAP. 2009; 47(01):12–18.
40. Dirtu D, Odochian L, Pui A, Humelnicu I. Thermal decomposition of ammonia. N2H4-an intermediate reaction product. Cen Eur J Chem. 2006;4(4):666–673
41. Kong X, Jin L, Wei M, Duan X. Antioxidant drugs intercalated into layered double hydroxide: Structure and in vitro release. Applied Clay Science. 2010;49(3):324–329.
42. Ho YS, Ofomaja AE. Pseudo-second-order model for lead ion sorption from aqueous solutions onto palm kernel fiber. J Hazd Mater. 2006;129(1–3):137–142.
43. Chen XT, Mi F, Zhang H, Zhang HQ. Facile synthesis of a novel magnetic core-shell hierarchical composite submicrospheres Fe3O4-CuNiAl-LDH under ambient conditions. Mater Lett. 2012;69:48–51